From: Patients as research partners in preference studies: learnings from IMI-PREFER
Hypothesized dimensions of impact to measure | Â | Â | Actual | Impacts | Reported | Â | Â | Â |
---|---|---|---|---|---|---|---|---|
 | COPD | Gene therapy | Hemophilia | MM | NMDb | NSCLCb | RA | RA preventive treatmentb |
I. Better quality research | Â | Â | Â | Â | Â | Â | Â | Â |
1. Research quality and research process: enhanced credibility and improved research | X | X | X | X | X | – | X | X |
2. New funding and funding opportunities: patient contributed to research proposal | – | – | – | – | – | – | – | X |
3. Research questions (e.g., which treatment attributes to assess), hypotheses, interventions and medical technologies become more relevant/usable for patients | X | X | X | X | X | – | X | X |
4. Research design, methods and study procedures become more appropriate, sensitive and/or ethically acceptable | X | X | X | X | X | – | X | X |
5. Recruitment, accrual rates, and retention improvements | X | – | X | X | X | X | – | X |
6. Representativeness/diversity of research subjects (i.e., inclusion of more hard-to-reach patients) | – | – | X | – | X | – | – | – |
7. Data collection procedures and data quality changes | X | X | X | X | X | – | X | X |
8. Intervention and/or survey implementation by patients | – | X (piloting) | – | – | X (piloting) | – | X (piloting) | X (pretesting) |
9. Data analysis and/or results interpretation by patients | – | – | X | X | – | X | X | X |
10. Researchers' knowledge and capacity increases | – | – | – | – | X | – | – | – |
11. Changes in researchers' attitudes about the value of the patient perspective | – | – | – | – | X | – | – | – |
12. More useful evidence for clinical and health policy decisionmaking | – | – | – | – | X | – | – | – |
13. More relevant evidence for entire spectrum of patients with targeted disease condition | – | – | – | – | X | – | – | – |
14. Changes to health outcomes, including overall population health, morbidity and mortality | – | – | – | – | – | – | – | – |
II. Other impacts | – | – | – | – | – | – | – | – |
1. Patient empowerment  (a) Patient or community research knowledge, skills and capacity  (b) Knowledge of community needs (empathy), services available, motivation to help community (citizenship literacy) | – | – | – | – | X (a and b) | – | – | – |
2. Increased translation, dissemination and uptake of results via improved dissemination to patients and the community | – | X | – | X | X | X | – | X |
3. Democracy and accountability  (a) Transparency  (b) Legitimacy  (c) Accountability  (d) Public trust in public institutions | – | (a) X (lay language summary) | – | (a) X (lay language summary) | (a) X (lay language summary) | (a) X (lay language summary) | – | (a) X (lay language summary) |
4. Moral obligation  (a) Fairness  (b) Respect and trust between researchers and engaged stakeholders  (c) More ethically acceptable research | – | – | – | – | (a, b, c) X | – | – | – |
 Total # of types of impacts reported | 5 | 7 | 7 | 8 | 15 | 4 | 6 | 10 |